Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial

Table 3 Bispectral index and haemodynamic data in the two study groups

Variable		Propofol + saline	Propofol + remifentanil
Variable		(n = 32) [Mean % difference from baseline]	(n = 26) [Mean % difference from baseline]
BIS	Baseline	96 (3)	97 (2)
	Before SLMA insertion^, *	36 (12) [63 %]	53 (14) [45 %]
	1 min after SLMA insertion^, *	37 (15) [64 %]	51 (15) [47 %]
	6 min after SLMA insertion^, *	28 (9) [71 %]	42 (16) [57 %]
Systolic BP (mmHg)	Baseline	125 (15)	131 (15)
	Before SLMA insertion^, *	108 (13) [14 %]	95 (15) [27 %]
	1 min after SLMA insertion^, *	111 (17) [11 %]	94 (15) [27 %]
	6 min after SLMA insertion*	97 (14) [23 %]	92 (11) [29 %]
Diastolic BP (mmHg)	Baseline	76 (10)	78 (12)
	Before SLMA insertion^, *	66 (11) [12 %]	54 (12) [29 %]
	1 min after SLMA insertion^, *	68 (11) [12 %]	56 (12) [29 %]
	6 min after SLMA insertion*	56 (11) [26 %]	55 (9) [28 %]
Heart rate (bpm)	Baseline	72 (18)	71 (10)
	Before SLMA insertion^, *	71 (8) [0.01 %]	58 (9) [18 %]
	1 min after SLMA insertion^, *	74 (12) [0,03 %]	58 (10) [18 %]
	6 min after SLMA insertion^, *	62 (10) [14 %]	54 (8) [24 %]

Data are expressed as mean (SD)
BIS bispectral index, BP blood pressure, SD standard deviation
*p < 0.05; significant difference from baseline (difference within the group)
**p < 0.05; significant difference between the propofol + saline and propofol + remifentanil groups by ANOVA with repeated measurements

ISSN: 1471-2253